Leqembi IQLIK injection training fits caregivers of people with early Alzheimer's who have confirmed amyloid buildup and a prescription for home use. People with unconfirmed memory loss, more advanced dementia, high bleeding risk, or missing brain scans need further review before training. Leqembi IQLIK is a subcutaneous autoinjector form of lecanemab-irmb for early Alzheimer's disease.
It became available in the U.S. for weekly initiation treatment on August 24, 2026, according to the BioArctic and Eisai press release. Training teaches a patient or caregiver to give the shots correctly and safely at home.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who may qualify for home injection training?
- Who needs further review first?
- What does caregiver training involve?
- What support and safety checks continue at home?
- Who may qualify for home injection training?
- Who needs further review first?
- What does caregiver training involve?
- What support and safety checks continue at home?
Who may qualify for home injection training?
People with mild cognitive impairment or mild dementia linked to Alzheimer's may qualify. The Alzheimer's Association treatment page states Leqembi products are indicated only for this early stage with confirmed elevated brain amyloid-beta pathology.
Qualifying also means the person can follow the prescribed schedule and safety checks. The initiation dose is 500 mg once weekly as two back-to-back 250-mg injections, then 360 mg weekly as maintenance after 18 months.
Who needs further review first?
People with memory complaints but no amyloid test result need further diagnostic review. Amyloid pathology must be confirmed by PET scan or spinal-fluid testing before treatment starts.
People with certain medical risks also need prescriber review. Those with two ApoE e4 gene copies face higher risk of brain swelling or bleeding, and people taking blood thinners or clot-prevention drugs face higher bleeding risk.
- confirmed early Alzheimer's with elevated amyloid: may proceed toward training
- unconfirmed memory loss: needs PET or spinal-fluid testing
- moderate or severe dementia: does not meet indication
- high bleeding risk, recent brain bleed, or missing baseline MRI: needs prescriber review
What does caregiver training involve?
Training starts under direct guidance from a health care provider. The Drugs.com summary of the FDA label states initiation requires supervision for at least two consecutive doses before home use is allowed.
The provider then decides whether home injections by the patient or caregiver are appropriate. Home dosing uses two consecutive injections of about 15 seconds each for each weekly initiation dose.
What support and safety checks continue at home?
Eisai and Biogen offer the LEQEMBI Companion program with Nurse Educators in person or virtually. Educators demonstrate autoinjector use and provide insurance help, tracking tools, and welcome-kit resources.
Home use still requires close medical follow-up for brain swelling or bleeding. The FDA Medication Guide via DailyMed carries a boxed warning for amyloid-related imaging abnormalities, sometimes fatal, and requires a baseline brain MRI plus scheduled MRIs during treatment. Report severe headache, confusion, vision change, dizziness, nausea, or unusual bleeding right away and keep each MRI appointment.
Who may qualify for home injection training?
People with mild cognitive impairment or mild dementia linked to Alzheimer's may qualify. The Alzheimer's Association treatment page states Leqembi products are indicated only for this early stage with confirmed elevated brain amyloid-beta pathology.
Qualifying also means the person can follow the prescribed schedule and safety checks. Managed Healthcare Executive reports the initiation dose is 500 mg once weekly as two back-to-back 250-mg injections, then 360 mg weekly as maintenance after 18 months.
Who needs further review first?
People with memory complaints but no amyloid test result need further diagnostic review. FDA prescribing information states amyloid pathology must be confirmed by PET scan or spinal-fluid testing before treatment starts.
People with certain medical risks also need prescriber review. Those with two ApoE e4 gene copies face higher risk of brain swelling or bleeding, and people taking blood thinners or clot-prevention drugs face higher bleeding risk.
- confirmed early Alzheimer's with elevated amyloid: may proceed toward training
- unconfirmed memory loss: needs PET or spinal-fluid testing
- moderate or severe dementia: does not meet indication
- high bleeding risk, recent brain bleed, or missing baseline MRI: needs prescriber review
What does caregiver training involve?
Training starts under direct guidance from a health care provider. The Drugs.com summary of the FDA label states initiation requires supervision for at least two consecutive doses before home use is allowed.
The provider then decides whether home injections by the patient or caregiver are appropriate. Home dosing uses two consecutive injections of about 15 seconds each for each weekly initiation dose.
What support and safety checks continue at home?
Eisai and Biogen state their LEQEMBI Companion program provides Nurse Educators in person or virtually. Educators demonstrate autoinjector use and provide insurance help, tracking tools, and welcome-kit resources.
Home use still requires close medical follow-up for brain swelling or bleeding. The FDA Medication Guide via DailyMed carries a boxed warning for amyloid-related imaging abnormalities, sometimes fatal, and requires a baseline brain MRI plus scheduled MRIs during treatment. Report severe headache, confusion, vision change, dizziness, nausea, or unusual bleeding right away and keep each MRI appointment.
